Testosterone Cypionate TRT: Diagnosis, Dosing and Monitoring

    Testosterone cypionate for TRT: who qualifies, 75 to 100 mg weekly or 150 to 200 mg every two weeks, what the first months feel like, blood tests and stop rules.

    Testosterone cypionate TRT is the most common form of testosterone replacement in the United States, and most of the questions men bring to it have label or guideline answers: who qualifies, how the dose is chosen, what the first weeks feel like, which blood tests are repeated and what makes a prescriber stop.

    This page follows the Depo-Testosterone label (Pfizer, revised September 2025), the Azmiro label (Azurity, 2025) and the Endocrine Society's 2018 clinical practice guideline, and marks the points where clinic practice runs ahead of both.

    Key takeaway
    A diagnosis needs symptoms plus low morning testosterone on two separate days; the guideline regimen is 75 to 100 mg weekly or 150 to 200 mg every two weeks, aiming for mid-normal levels; hematocrit, blood pressure and PSA are rechecked at three to six months and then yearly; a hematocrit above 54% is the usual reason to pause.

    Who Qualifies

    The label indicates testosterone cypionate for two conditions:

    1. 1Primary hypogonadism: testicular failure from cryptorchidism, torsion, orchitis or orchidectomy
    2. 2Hypogonadotropic hypogonadism: pituitary or hypothalamic disease, gonadotropin deficiency

    It states that safety and efficacy in "age-related hypogonadism" have not been established.

    The Endocrine Society guideline adds the standard most clinics use: a diagnosis only in men with symptoms and signs of deficiency and "unequivocally and consistently low" serum testosterone, measured fasting in the morning and confirmed by a repeat. Men whose total testosterone sits near the lower limit, or who have conditions that alter SHBG (obesity, thyroid or liver disease), get a free testosterone measurement before a decision.

    Who the guideline says should not start:

    1. 1Men planning fertility in the near term
    2. 2Breast or prostate cancer; a palpable prostate nodule; PSA above 4 ng/mL (above 3 at higher prostate-cancer risk) without urological evaluation
    3. 3Hematocrit above 50%
    4. 4Untreated severe sleep apnea; severe lower urinary tract symptoms
    5. 5Uncontrolled heart failure; heart attack or stroke within the previous six months

    The label itself contraindicates breast or prostate carcinoma and serious cardiac, hepatic or renal disease, and says the product is not recommended with uncontrolled hypertension.


    Choosing the Dose

    Starting regimens and what they produce

    Regimen
    Source
    Blood-level pattern

    150 to 200 mg every 2 weeks

    Label range; Endocrine Society

    Peak around day 3 (758 ng/dL mean after 200 mg in the Azmiro study), trough near baseline by day 14

    75 to 100 mg weekly

    Endocrine Society

    Smaller peak and trough; most clinics' default

    50 mg twice weekly or weekly subcutaneous

    Published clinic practice, off-label

    Flattest curve; normal male range reached in all 63 patients in a 2017 cohort

    The label's 50 to 400 mg every two to four weeks covers every historical schedule; the guideline's narrower regimen reflects pharmacokinetics.

    With an eight-day half-life, a 200 mg dose every two weeks swings a man from above the reference range in the first days to near his untreated level before the next injection. The mood, energy and libido changes that track those swings are the most common complaint in the first months. Weekly or twice-weekly dosing of the same total amount flattens the curve.

    The mechanics of measuring a dose from a 200 mg/mL vial, syringe choice and the intramuscular versus subcutaneous question are in the dosage and injection guide.


    What the First Months Feel Like

    Published trials of testosterone in hypogonadal men put the timeline roughly as follows:

    When each effect of testosterone therapy appearsLibido, sexual thoughts3 to 6 weeksMood and energy6 to 12 weeksHemoglobin riseplateau by a yearLean mass, strength3 to 6 monthsBone density1 to 2 years013265278104Weeks on treatment; from published trials, individual timing varies
    1. 1Weeks 3 to 6: libido and sexual thoughts change
    2. 2Weeks 6 to 12: mood and energy
    3. 3Month 3: hemoglobin has risen; it plateaus around a year
    4. 4Months 3 to 6: lean mass and strength shift
    5. 5A year or more: bone density

    The first blood draw at three months is timed for the hematocrit and the testosterone level rather than for symptoms.

    Men who feel nothing by month three on a weekly schedule with mid-normal levels are the ones a prescriber re-evaluates. The guideline's advice is to stop therapy that does not help rather than raise the dose until it does.

    Monitoring Schedule

    Monitoring the Endocrine Society recommends

    When
    What
    Action threshold

    Before starting

    Morning total testosterone twice; hematocrit; PSA and digital rectal exam in men 40 to 69 and older; blood pressure

    Hematocrit above 50%, PSA above 4 (or 3 at higher risk) defer treatment

    3 to 6 months

    Testosterone (mid-interval for injections), hematocrit, PSA, symptoms, blood pressure

    Hematocrit above 54%: stop until it falls, then restart lower; PSA rise above 1.4 ng/mL in a year or above 4 ng/mL: urology referral

    Yearly

    Same panel, plus bone density every 1 to 2 years in men with osteoporosis or low-trauma fracture

    Continue only if symptoms improved and levels are in range

    For injections, the guideline says to draw testosterone midway between doses and aim for the mid-normal range. A trough draw is used when the question is whether the interval is too long.

    The label asks for periodic hemoglobin and hematocrit "to detect polycythemia," periodic blood pressure, and notes that serum cholesterol may rise. The Azmiro label's hematocrit rule is explicit: check that it is not elevated before starting, stop if it rises, and stop permanently if it rises again after a restart. What those numbers mean is on the side effects page.


    Fertility, Estrogen and Other Questions

    Testosterone from a vial switches off the pituitary signals (LH and FSH) that drive the testes, so sperm production falls, often to zero; the label warns of oligospermia and azoospermia. The guideline's advice to men who want children is not to start, or to discuss alternatives with a reproductive endocrinologist.

    Estrogen rises with testosterone because aromatase converts a fraction of it. The label lists gynecomastia as a reaction, but routine aromatase-inhibitor use on TRT is not part of the guideline and is covered under side effects rather than as standard care.

    Practical points that follow from Schedule III status:

    1. 1Prescriptions are limited to five refills in six months under federal rules
    2. 2Telehealth prescribing has its own rules
    3. 3Travelling with vials across borders needs documentation

    Cost of a TRT Prescription

    The drug is the cheapest part. GoodRx prices in November 2026:

    1. 1Generic 200 mg/mL, 1 mL vial: $13 to $30 with a coupon
    2. 2Brand Depo-Testosterone, 1 mL vial: about $13 to $46 depending on pharmacy
    3. 3Generic 10 mL vial: typically $50 to $120 retail

    A weekly 100 mg schedule uses half a mL a week, so a 10 mL vial lasts roughly five months. Clinic fees, blood panels and supplies usually cost more than the testosterone. Insurance generally covers the drug for a documented diagnosis; the products page lists what a pharmacy vial should look like.

    Frequently Asked Questions

    There is no single cutoff in the label. The Endocrine Society requires symptoms plus consistently low morning total testosterone on two days, with free testosterone checked when total is borderline or SHBG is abnormal. Most US laboratories set the lower reference limit near 264 to 300 ng/dL.

    The label allows every two to four weeks; the Endocrine Society regimen is 75 to 100 mg weekly or 150 to 200 mg every two weeks. Many clinics use weekly or twice-weekly dosing for steadier levels.

    Testosterone, hematocrit and hemoglobin, PSA in men over 40, and blood pressure at three to six months and then yearly; lipids and liver tests are often added. Hematocrit above 54% is the usual stop point.

    Libido and mood changes in the first 3 to 12 weeks; muscle, body composition and hemoglobin over 3 to 12 months; bone density over a year or more.

    It suppresses sperm production, sometimes completely, and the guideline advises men planning children not to start. Recovery after stopping takes months and is not guaranteed.

    The label says safety and efficacy for age-related hypogonadism have not been established. Prescribers who treat it do so off the indication, with the same monitoring.

    Cypionat.com is an independent educational resource. We are not affiliated with Pfizer, Azurity or any manufacturer, pharmacy or clinic. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.

    Advertising